Healthcare

Harmony Biosciences is a profitable rare-neurology company powered by Wakix, with strong cash generation, low leverage, and margins well above most biotech peers. The key long-term question is how effectively it can turn that financial strength into a broader product portfolio.

ICU Medical supplies hospitals with infusion systems, disposables, and critical care products. Its appeal rests on recurring consumable demand and room for margin recovery after the Smiths Medical deal, making execution and cash generation central to the long-term picture.

Haw Par pairs the global Tiger Balm franchise with strong cash generation and an unusually clean balance sheet. The business sits in a steady self-care niche, and its valuation remains restrained relative to many healthcare peers despite solid long-term growth.

Guardian Pharmacy Services supplies medications and pharmacy support to long-term care and senior living facilities. Aging demographics, rising cash flow, and a stronger balance sheet make its niche worth a closer look, especially as profitability has rebounded.

Structure Therapeutics is developing oral medicines for obesity and other chronic diseases, aiming to bring pill-based options into a market dominated by injections. Its platform and clean balance sheet stand out, while future clinical results remain the central driver.

Dyne Therapeutics is building muscle-targeted genetic medicines for rare neuromuscular diseases. The appeal rests on a focused platform, large unmet need, and multiple clinical catalysts that could reshape its long-term commercial potential.

Enliven Therapeutics is building targeted cancer drugs around two lead programs, ELVN-001 and ELVN-002. Strong stock momentum, a very low-debt balance sheet, and exposure to precision oncology make its clinical progress especially important to follow.